JFG
SPRY icon

Jefferies Financial Group’s ARS Pharmaceuticals SPRY Stock Holding History

Jefferies Financial Group’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-60,190
Closed -$403K – 1966
2023
Q2 		$403K Buy
+60,190
New +$402K ﹤0.01% 1247

Other funds holding SPRY

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
CST
Charles Schwab Trust Henderson, Nevada $1.79B AUM 17.47% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KPF
K2 Principal Fund Toronto, Ontario, Canada $1.43B AUM 29.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Jefferies Financial Group's SPRY Position: Q3 2023 in Review

Jefferies Financial Group sold out of ARS Pharmaceuticals (SPRY) in Q3 2023, closing a stake of 60,190 shares — an estimated $403K sold.

Jefferies Financial Group first reported a position in SPRY in Q2 2023 and held it in 1 quarter. The position peaked at $403K in Q2 2023. 97 funds tracked by Wall St. Rank hold SPRY as of Q3 2023.

  • Jefferies Financial Group reported no remaining ARS Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • Jefferies Financial Group sold 60,190 ARS Pharmaceuticals shares in Q3 2023, an estimated $403K.
  • Jefferies Financial Group first reported a position in ARS Pharmaceuticals in Q2 2023 and held it in 1 quarter.
  • Jefferies Financial Group's ARS Pharmaceuticals position peaked at $403K in Q2 2023.
  • 97 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q3 2023.

Based on Jefferies Financial Group's 13F filing for Q3 2023, filed 14 Nov 2023.